MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
CERT stock logo

CERT

Certara, Inc.

$5.18
-0.04
 (-0.77%)
Exchange:  NASDAQ
Market Cap:  805.825M
Shares Outstanding:  132.408M
Delayed data
Calculate CERT Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Healthcare Information Services
   
CEO:  Jon Resnick
Full Time Employees:  1487
Address: 
100 Overlook Center
Princeton
NJ
8540
US
Website:  https://www.certara.com
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company’s core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company’s clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/11 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue354,337385,148418,838
Gross Profit213,315230,632257,712
EBITDA23,84472,36983,910
Operating Income-40,774-1,73121,016
Net Income-55,357-12,051-1,595

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets1,563,1401,575,1041,556,582
Total Liabilities516,300516,448493,787
Total Stockholders Equity1,046,8401,058,6561,062,795
Total Debt302,567311,89711,401
Cash and Cash Equivalents234,951179,183189,392

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow82,75580,46696,325
Capital Expenditure-15,322-1,625-1,760
Free Cash Flow67,43378,84194,565
Net Income-55,357-12,051-1,595
Net Change in Cash-4,737-55,76810,209

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2029Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)447,509.072Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)465,785.583Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)456,778.503Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)82,827.416Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)86,210.132Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)84,543.053Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)86,486.274Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)91,107.237Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)88,829.637Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)147,647.585Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)153,677.592Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)150,705.868Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)0.550Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)0.570Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.540Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)3Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
385.148M  ?P/S
 (TTM)
: 
1.99
?Net Income
 (TTM)
: 
-12051000  ?P/E
 (TTM)
: 
-56.1
?Enterprise Value
 (TTM)
: 
696.65M  ?EV/FCF
 (TTM)
: 
7.84
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-0.01  ?ROIC
 (TTM)
: 
0.01
?Net Debt
 (TTM)
: 
132.714M  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
0.83  ?Current Ratio
 (TTM)
: 
1.88

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
13.63Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates CERT intrinsic value between $7.23 – $9.52 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about CERT valuation

Is Certara, Inc. (CERT) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Certara, Inc. (CERT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is CERT a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CERT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is CERT’s P/E ratio?

You can see CERT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for CERT?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is CERT a good long-term investment?

Whether CERT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

CERT

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.77
MARKETSnap

Trading Metrics:

Open: 5.22   Previous Close: 5.22
Day Low: 5.14   Day High: 5.46
Year Low: 4.45   Year High: 13.88
Price Avg 50: 5.65   Price Avg 200: 8.52
Volume: 4.341M   Average Volume: 3.957M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
26-05-2026 16:54
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Certara, Inc. - CERT
Certara, Inc. (CERT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
03-06-2026 19:31
Certara, Inc. (CERT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
24-05-2026 14:14
CERT Investors Have Opportunity to Join Certara, Inc. Fraud Investigation with the Schall Law Firm
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
18-05-2026 19:00
CERT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
19-05-2026 17:40
Certara, Inc. (CERT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Certara to Participate in Upcoming Investor Conferences
27-02-2026 08:30
Certara to Participate in Upcoming Investor Conferences

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read